Theodoros G Soldatos
Overview
Explore the profile of Theodoros G Soldatos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
591
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ates O, Pandey G, Gousiopoulos A, Soldatos T
Front Artif Intell
. 2024 Nov;
7:1424371.
PMID: 39525498
Recent developments on artificial intelligence (AI) and machine learning (ML) techniques are expected to have significant impact on public health in several ways. Indeed, modern AI/ML methods have been applied...
2.
Brock S, Soldatos T, Jackson D, Diella F, Hornischer K, Schafer A, et al.
Front Mol Med
. 2024 Aug;
2:1035215.
PMID: 39086977
Since early 2020 the COVID-19 pandemic has paralyzed the world, resulting in more than half a billion infections and over 6 million deaths within a 28-month period. Knowledge about the...
3.
Brock S, Jackson D, Soldatos T, Hornischer K, Schafer A, Diella F, et al.
Front Mol Med
. 2024 Aug;
2:1035290.
PMID: 39086962
Infection with SARS-CoV-2 coronavirus causes systemic, multi-faceted COVID-19 disease. However, knowledge connecting its intricate clinical manifestations with molecular mechanisms remains fragmented. Deciphering the molecular basis of COVID-19 at the whole-patient...
4.
Kim S, Lahu G, Vakilynejad M, Soldatos T, Jackson D, Lesko L, et al.
Clin Transl Sci
. 2022 Feb;
15(6):1430-1438.
PMID: 35191192
Immunotherapy became a key pillar of cancer therapeutics with the approvals of ipilimumab, nivolumab, and pembrolizumab, which inhibit either cytotoxic T-lymphocyte antigen-4 (CTLA-4) or programmed death-1 (PD-1) that are negative...
5.
Soldatos T, Kim S, Schmidt S, Lesko L, Jackson D
CPT Pharmacometrics Syst Pharmacol
. 2022 Feb;
11(5):540-555.
PMID: 35143713
Promising drug development efforts may frequently fail due to unintended adverse reactions. Several methods have been developed to analyze such data, aiming to improve pharmacovigilance and drug safety. In this...
6.
Kim S, Lahu G, Vakilynejad M, Soldatos T, Jackson D, Lesko L, et al.
Clin Transl Sci
. 2022 Jan;
15(4):1003-1013.
PMID: 35014203
Adverse drug reactions (ADRs) of targeted therapy drugs (TTDs) are frequently unexpected and long-term toxicities detract from exceptional efficacy of new TTDs. In this proof-of-concept study, we explored how molecular...
7.
Schotland P, Racz R, Jackson D, Soldatos T, Levin R, Strauss D, et al.
Clin Pharmacol Ther
. 2020 Oct;
109(5):1232-1243.
PMID: 33090463
We improved a previous pharmacological target adverse-event (TAE) profile model to predict adverse events (AEs) on US Food and Drug Administration (FDA) drug labels at the time of approval. The...
8.
Hirotsu Y, Schmidt-Edelkraut U, Nakagomi H, Sakamoto I, Hartenfeller M, Narang R, et al.
Int J Mol Sci
. 2020 Jun;
21(11).
PMID: 32486089
variants are prognostic biomarkers for hereditary breast and/or ovarian cancer (HBOC) syndrome and predictive biomarkers for PARP inhibition. In this study, we benchmarked the classification of variants from patients with...
9.
Schaefer A, Sachpekidis C, Diella F, Doerks A, Kratz A, Meisel C, et al.
Cancers (Basel)
. 2020 Apr;
12(4).
PMID: 32325840
Immune checkpoint inhibition represents an important therapeutic option for advanced melanoma patients. Results from clinical studies have shown that treatment with the inhibitors Pembrolizumab and Nivolumab provides improved response and...
10.
Sachpekidis C, Jackson D, Soldatos T
Pharmaceuticals (Basel)
. 2019 Sep;
12(4).
PMID: 31546999
The development of monoclonal antibodies has dramatically changed the outcome of patients with non-Hodgkin's lymphoma (NHL), the most common hematological malignancy. However, despite the satisfying results of monoclonal antibody treatment,...